1
|
Hassan M, Abdelnabi HA, Mohsin S. Harnessing the Potential of PLGA Nanoparticles for Enhanced Bone Regeneration. Pharmaceutics 2024; 16:273. [PMID: 38399327 PMCID: PMC10892810 DOI: 10.3390/pharmaceutics16020273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Revised: 01/25/2024] [Accepted: 02/05/2024] [Indexed: 02/25/2024] Open
Abstract
Recently, nanotechnologies have become increasingly prominent in the field of bone tissue engineering (BTE), offering substantial potential to advance the field forward. These advancements manifest in two primary ways: the localized application of nanoengineered materials to enhance bone regeneration and their use as nanovehicles for delivering bioactive compounds. Despite significant progress in the development of bone substitutes over the past few decades, it is worth noting that the quest to identify the optimal biomaterial for bone regeneration remains a subject of intense debate. Ever since its initial discovery, poly(lactic-co-glycolic acid) (PLGA) has found widespread use in BTE due to its favorable biocompatibility and customizable biodegradability. This review provides an overview of contemporary advancements in the development of bone regeneration materials using PLGA polymers. The review covers some of the properties of PLGA, with a special focus on modifications of these properties towards bone regeneration. Furthermore, we delve into the techniques for synthesizing PLGA nanoparticles (NPs), the diverse forms in which these NPs can be fabricated, and the bioactive molecules that exhibit therapeutic potential for promoting bone regeneration. Additionally, we addressed some of the current concerns regarding the safety of PLGA NPs and PLGA-based products available on the market. Finally, we briefly discussed some of the current challenges and proposed some strategies to functionally enhance the fabrication of PLGA NPs towards BTE. We envisage that the utilization of PLGA NP holds significant potential as a potent tool in advancing therapies for intractable bone diseases.
Collapse
Affiliation(s)
| | | | - Sahar Mohsin
- Department of Anatomy, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain P.O. Box 15551, United Arab Emirates
| |
Collapse
|
2
|
Carneiro S, Müller JT, Merkel OM. Targeted Molecular Therapeutics for Pulmonary Diseases: Addressing the Need for Precise Drug Delivery. Handb Exp Pharmacol 2024; 284:313-328. [PMID: 38177399 DOI: 10.1007/164_2023_703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2024]
Abstract
Respiratory diseases are a major concern in public health, impacting a large population worldwide. Despite the availability of therapies that alleviate symptoms, selectively addressing the critical points of pathopathways remains a major challenge. Innovative formulations designed for reaching these targets within the airways, enhanced selectivity, and prolonged therapeutic effects offer promising solutions. To provide insights into the specific medical requirements of chronic respiratory diseases, the initial focus of this chapter is directed on lung physiology, emphasizing the significance of lung barriers. Current treatments involving small molecules and the potential of gene therapy are also discussed. Additionally, we will explore targeting approaches, with a particular emphasis on nanoparticles, comparing targeted and non-targeted formulations for pulmonary administration. Finally, the potential of inhaled sphingolipids in the context of respiratory diseases is briefly discussed, highlighting their promising prospects in the field.
Collapse
Affiliation(s)
- Simone Carneiro
- Department of Pharmacy, Pharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Joschka T Müller
- Department of Pharmacy, Pharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-University Munich, Munich, Germany
| | - Olivia M Merkel
- Department of Pharmacy, Pharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-University Munich, Munich, Germany.
- Center for NanoScience (CeNS), Ludwig-Maximilians-University Munich, Munich, Germany.
- Institute of Lung Health and Immunity (LHI) and Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, German Center for Lung Research (DZL), Munich, Germany.
| |
Collapse
|
3
|
Şahin Bektay H, Sağıroğlu AA, Bozali K, Güler EM, Güngör S. The Design and Optimization of Ceramide NP-Loaded Liposomes to Restore the Skin Barrier. Pharmaceutics 2023; 15:2685. [PMID: 38140026 PMCID: PMC10747297 DOI: 10.3390/pharmaceutics15122685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 10/08/2023] [Accepted: 10/25/2023] [Indexed: 12/24/2023] Open
Abstract
The impairment of skin integrity derived from derangement of the orthorhombic lateral organization is mainly caused by dysregulation of ceramide amounts in the skin barrier. Ceramides, fatty acids, and cholesterol-containing nano-based formulations have been used to impair the skin barrier. However, there is still a challenge to formulate novel formulations consisting of ceramides due to their chemical structure, poor aqueous solubility, and high molecular weight. In this study, the design and optimization of Ceramide 3 (CER-NP)-loaded liposomes are implemented based on response surface methodology (RSM). The optimum CER-NP-loaded liposome was selected based on its particle size (PS) and polydispersity index (PDI). The optimum CER-NP-loaded liposome was imagined by observing the encapsulation by using a confocal laser scanning microscope (CLSM) within fluorescently labeled CER-NP. The characteristic liquid crystalline phase and lipid chain conformation of CER-NP-loaded liposomes were determined using attenuated total reflectance infrared spectroscopy (ATR-IR). The CER-NP-loaded liposomes were imagined using a field emission scanning electron microscope (FE-SEM). Finally, the in vitro release of CER-NP from liposomes was examined using modified Franz Cells. The experimental and predicted results were well correlated. The CLSM images of optimized liposomes were conformable with the other studies, and the encapsulation efficiency of CER-NP was 93.84 ± 0.87%. ATR-IR analysis supported the characteristics of the CER-NP-loaded liposome. In addition, the lipid chain conformation shows similarity with skin barrier lipid organization. The release pattern of CER-NP liposomes was fitted with the Korsmeyer-Peppas model. The cytotoxicity studies carried out on HaCaT keratinocytes supported the idea that the liposomes for topical administration of CER-NP could be considered relatively safe. In conclusion, the optimized CER-NP-loaded liposomes could have the potential to restore the skin barrier function.
Collapse
Affiliation(s)
- Hümeyra Şahin Bektay
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul 34116, Türkiye
- Health Science Institute, Istanbul University, Istanbul 34126, Türkiye
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Bezmialem Vakıf University, Istanbul 34093, Türkiye
| | - Ali Asram Sağıroğlu
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Bezmialem Vakıf University, Istanbul 34093, Türkiye
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University-Cerrahpaşa, Istanbul 34500, Türkiye
| | - Kübra Bozali
- Department of Medical Biochemistry, Faculty of Hamidiye Medicine, University of Health Science, Istanbul 34668, Türkiye
| | - Eray Metin Güler
- Department of Medical Biochemistry, Faculty of Hamidiye Medicine, University of Health Science, Istanbul 34668, Türkiye
| | - Sevgi Güngör
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul 34116, Türkiye
| |
Collapse
|
4
|
Huang A, Guo F, Yu Z, Liu P, Dong S, Zhang Y, Kong Y, Kong X, Li T, Luo Y, Xia H, Shi K, Xia J. Engineered Apoptosis-Bioinspired Nanoparticles Initiate Immune Cascade for Cancer Immunotherapy of Malignant Ascites. ACS APPLIED MATERIALS & INTERFACES 2023; 15:10371-10382. [PMID: 36786554 DOI: 10.1021/acsami.2c19769] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
Malignant ascites (MA) is a common symptom of peritoneal metastasis in liver cancer. Cancer immunotherapy can modulate immune cells to induce antitumor immune efficiency. Reprogramming tumor immune microenvironment (TIME) is a momentous strategy to overcome immunosuppression and achieve immune functional normalization. Inspired by the inherent apoptotic bodies and vesicles, we proposed and systematically studied engineered apoptosis-bioinspired nanoparticles (EBN) for cancer immunotherapy of MA. Using both in vitro and in vivo experimental validations, we elucidated that EBN could be efficiently engulfed by the tumor-associated macrophages (TAMs) and manipulate their polarization. Moreover, a boosted immune cascade response as a result of heightening cytotoxic T-lymphocytes (CTLs) activity was investigated. Based on these results, EBN was confirmed to have strong immune cascade activation capability. Remarkably, the injection of EBN further reduced ascites volume and reformed immune cell subtypes, compared to the injection of either PBS or free TMP195 alone. In short, this novel nanodrug delivery system (NDDS) represents a prospective immunotherapeutic approach for clinical therapeutics of hepatoma ascites and other malignant effusion.
Collapse
Affiliation(s)
- Anmin Huang
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
- Translational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
- The First Clinical Medical College, Wenzhou Medical University, Wenzhou 325000, China
| | - Feixia Guo
- Translational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
| | - Zhijie Yu
- Wenzhou Key Laboratory of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
| | - Pixu Liu
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
| | - Shiying Dong
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
- The First Clinical Medical College, Wenzhou Medical University, Wenzhou 325000, China
| | - Yunjie Zhang
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
- The First Clinical Medical College, Wenzhou Medical University, Wenzhou 325000, China
| | - Yifan Kong
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
- The First Clinical Medical College, Wenzhou Medical University, Wenzhou 325000, China
| | - Xiuyan Kong
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
- The First Clinical Medical College, Wenzhou Medical University, Wenzhou 325000, China
| | - Ting Li
- The First Clinical Medical College, Wenzhou Medical University, Wenzhou 325000, China
| | - Yongde Luo
- The First Affiliated Hospital & School of Pharmacological Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325000, China
| | - Hongping Xia
- Zhongda Hospital, School of Medicine & Advanced Institute for Life and Health, Southeast University, Nanjing 210009, China
| | - Keqing Shi
- Translational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
| | - Jinglin Xia
- Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
- Department of Intervention, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
| |
Collapse
|
5
|
Poly(Lactic-co-glycolic) Acid and Phospholipids Hybrid Nanoparticles for Regeneration of Biological Tissue. CHEMENGINEERING 2022. [DOI: 10.3390/chemengineering6010010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
In tissue regeneration, biomaterials facilitate biological processes. However, a treatment with biomaterials will be successful only if supported by simple and inexpensive technologies which stimulate the regenerative processes. The present study focused on the possibility of creating formulations from which then to obtain suitable materials for the regeneration of heart tissue. The experimental procedure for precipitation of polymer- nanoparticles was modified ad hoc to obtain hybrid poly lactic-co-glycolic acid (PLGA)-phospholipid nanoparticles. The properties of the formulations produced by direct PLGA-phospholipid co-precipitation depend on the mass ratio R= polymer mass/phospholipid mass. The value of this parameter allows us to modulate the properties of the formulations. Formulations with R = 1.5, 2.3, 4, and 9 were prepared, and for each of them the particle-size distribution obtained by dynamic light scattering was studied. All samples showed that the hydrodynamic diameter decreases with increasing R value. This behavior is interpreted as polymer coil shrinkage due to contacts with the non-solvent. The spreadability and ease of obtaining thin sheets were evaluated for each formulation. The formulation with R=4 resulted in a homogeneous and easily workable material in thin sheets.
Collapse
|
6
|
Farinha D, Migawa M, Sarmento-Ribeiro A, Faneca H. A Combined Antitumor Strategy Mediated by a New Targeted Nanosystem to Hepatocellular Carcinoma. Int J Nanomedicine 2021; 16:3385-3405. [PMID: 34040370 PMCID: PMC8141275 DOI: 10.2147/ijn.s302288] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2021] [Accepted: 04/27/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Hepatocellular carcinoma (HCC) is one of the main causes of cancer-related death. Sorafenib, which is the first-line therapy for this disease, is associated with reduced therapeutic efficacy that could potentially be overcome by combination with selumetinib. In this context, the main goal of this work was to develop a new nanosystem, composed of a polymeric core coated by a lipid bilayer containing the targeting ligand GalNAc, to specifically and efficiently co-deliver both drugs into HCC cells, in order to significantly increase their therapeutic efficacy. METHODS The physicochemical characterization of hybrid nanosystems (HNP) and their components was performed by dynamic light scattering, zeta potential, matrix-assisted laser desorption ionization - time of flight mass spectroscopy, and transmission electron microscopy. Cellular binding, uptake and specificity of HNP were evaluated through flow cytometry and confocal microscopy. The therapeutic activity was evaluated namely through: cell viability by the Alamar Blue assay; cell death by flow cytometry using FITC-Annexin V; caspases activity by luminescence; mitochondrial membrane potential by flow cytometry; and molecular target levels by Western blot. RESULTS The obtained data show that these hybrid nanosystems present high stability and loading capacity of both drugs, and suitable physicochemical properties, namely in terms of size and surface charge. Moreover, the generated formulation allows to circumvent drug resistance and presents high specificity, promoting great cell death levels in HCC cells, but not in non-tumor cells. This potentiation of the antitumor effect of co-loaded drugs was carried out by an increased programmed cell death, being associated with a strong reduction in the mitochondrial membrane potential, a significant increase in the activity of caspases 3/7 and caspase 9, and much greater number of annexin V-positive cells. CONCLUSION The developed formulation resulted in a high and synergistic antitumor effect, revealing a translational potential to improve therapeutic approaches against HCC.
Collapse
Affiliation(s)
- Dina Farinha
- CNC - Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal
- Institute for Interdisciplinary Research (IIIUC), University of Coimbra, Coimbra, Portugal
| | | | - Ana Sarmento-Ribeiro
- CNC - Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal
- Laboratory of Oncobiology and Hematology (LOH) and University Clinic of Hematology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
- Clinical Hematology Department, Centro Hospitalar Universitário de Coimbra (CHUC), Coimbra, Portugal
| | - Henrique Faneca
- CNC - Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal
- Institute for Interdisciplinary Research (IIIUC), University of Coimbra, Coimbra, Portugal
| |
Collapse
|
7
|
Rizwanullah M, Ahmad J, Amin S, Mishra A, Ain MR, Rahman M. Polymer-Lipid Hybrid Systems: Scope of Intravenous-To-Oral Switch in Cancer Chemotherapy. ACTA ACUST UNITED AC 2020. [DOI: 10.2174/2468187309666190514083508] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Cancer chemotherapeutic administration by oral route has the potential to create
“hospitalization free chemotherapy”. Such a therapeutic approach will improve patient
compliance and significantly reduce the cost of treatment. In current clinical practice,
chemotherapy is primarily carried out by intravenous injection or infusion and leads
to various unwanted effects. Despite the presence of oral delivery challenges like poor
aqueous solubility, low permeability, drug stability and substrate for multidrug efflux
transporter, cancer chemotherapy delivery through oral administration has gained much
attention recently due to having more patient compliance compared to the intravenous
mode of administration. In order to address the multifaceted oral drug delivery challenges,
a hybrid delivery system is conceptualized to merge the benefits of both polymeric
and lipid-based drug carriers. Polymer-lipid hybrid systems have presented various significant
benefits as an efficient carrier to facilitate oral drug delivery by surmounting the
different associated obstacles. This carrier system has been found suitable to overcome
the numerous oral absorption hindrances and facilitate the intravenous-to-oral switch in
cancer chemotherapy. In this review, we aimed to discuss the different biopharmaceutic
challenges in oral delivery of cancer chemotherapy and how this hybrid system may provide
solutions to such challenges.
Collapse
Affiliation(s)
- Md. Rizwanullah
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi- 110062, India
| | - Javed Ahmad
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, UP-229010, India
| | - Saima Amin
- Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi- 110062, India
| | - Awanish Mishra
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, UP-229010, India
| | | | - Mahfoozur Rahman
- Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences (SHUATS) Allahabad, UP-211007, India
| |
Collapse
|
8
|
Inhalable hybrid nanocarriers for respiratory disorders. TARGETING CHRONIC INFLAMMATORY LUNG DISEASES USING ADVANCED DRUG DELIVERY SYSTEMS 2020. [PMCID: PMC7499343 DOI: 10.1016/b978-0-12-820658-4.00013-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Rapid advancements in the field of drug delivery lead to increased use of inhalable formulations as they are cost effective, noninvasive, and targeted and have less systemic side effects and above all better patient compliance. Development of inhalable hybrid systems has offered manifold advantages to this area of drug delivery. Inclusion of polymer and lipid, inorganic and organic substances, and metallic nanoparticles all of them aim to achieve codelivery of drugs which are incompatible in single phase systems. The recent progress in nanotechnology has gained momentum toward delivery of siRNA and miRNA and vaccines to the targeted site. The present work is an attempt to compile all the hybrid and inhalable systems to give readers an overview toward this delivery system as much more work is needed in this field to achieve better resolution of inflammatory disorders.
Collapse
|
9
|
Chen J, Khiste SK, Fu X, Roy KR, Dong Y, Zhang J, Liu M, Liu YY, Liu Z. Rubusoside-assisted solubilization of poorly soluble C 6-Ceramide for a pilot pharmacokinetic study. Prostaglandins Other Lipid Mediat 2019; 146:106402. [PMID: 31841664 DOI: 10.1016/j.prostaglandins.2019.106402] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2019] [Revised: 10/22/2019] [Accepted: 12/03/2019] [Indexed: 12/30/2022]
Abstract
Although C6-Ceramide has attracted much attention as a possible tumor suppressor, the delivery of C6-Ceramide is still challenging due to its inherent hydrophobicity and insolubility. In this study we explored the use of a natural compound rubusoside (RUB) as a solubilizer to enhance the solubility of a fluorescence-labeled C6-Ceramide (NBD C6-Ceramide) and to characterize its pharmacokinetics and tissue distribution in an animal model. RUB significantly enhanced the solubility of NBD C6-Ceramide by forming nanomicelles, and efficiently delivered NBD C6-Ceramide in rats by oral and intravenous administration. RUB loaded 1.96 % of NBD C6-Ceramide in the nanomicelles and solubilized it to a concentration of 3.6 mg/mL in water. NBD C6-Ceramide in nanomicelles remained stable in aqueous solutions, allowing intravenous administration without the use of any organic solvents or surfactants. After oral administration, NBD C6-Ceramide rapidly rose to peak plasma concentrations within the first 90 min, distributed to tissues, and remained in vivo for more than 24 h. Tissular levels of NBD C6-Ceramide from high to low were associated with heart, lung, cerebellum, testicle, spleen, liver, kidney, and brain. Altogether, our study demonstrated that RUB-assisted nanomicelles can serve as an efficient and convenient delivery system for short-chain C6-Ceramide and enable in vivo evaluation of potential new cancer treatments.
Collapse
Affiliation(s)
- Jianzhong Chen
- School of Renewable Natural Resources, LSU Agricultural Center, Louisiana State University, Baton Rouge 70803, USA
| | - Sachin K Khiste
- Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71203, USA
| | - Xiaomei Fu
- School of Renewable Natural Resources, LSU Agricultural Center, Louisiana State University, Baton Rouge 70803, USA; School of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China
| | - Kartik R Roy
- Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71203, USA
| | - Yixuan Dong
- School of Renewable Natural Resources, LSU Agricultural Center, Louisiana State University, Baton Rouge 70803, USA
| | - Jian Zhang
- School of Renewable Natural Resources, LSU Agricultural Center, Louisiana State University, Baton Rouge 70803, USA; School of Perfume and Aroma Technology, Shanghai Institute of Technology, Shanghai 201418, China
| | - Mei Liu
- School of Renewable Natural Resources, LSU Agricultural Center, Louisiana State University, Baton Rouge 70803, USA; School of Pharmacy, Guangzhou University of Traditional Chinese Medicine, Guangzhou 330004, China
| | - Yong-Yu Liu
- Basic Pharmaceutical Sciences, School of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71203, USA
| | - Zhijun Liu
- School of Renewable Natural Resources, LSU Agricultural Center, Louisiana State University, Baton Rouge 70803, USA.
| |
Collapse
|
10
|
Khiste SK, Liu Z, Roy KR, Uddin MB, Hosain SB, Gu X, Nazzal S, Hill RA, Liu YY. Ceramide-Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations. Mol Cancer Ther 2019; 19:564-574. [PMID: 31645443 DOI: 10.1158/1535-7163.mct-19-0366] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Revised: 07/24/2019] [Accepted: 10/14/2019] [Indexed: 12/15/2022]
Abstract
Ceramide (Cer) is an active cellular sphingolipid that can induce apoptosis or proliferation-arrest of cancer cells. Nanoparticle-based delivery offers an effective approach for overcoming bioavailability and biopharmaceutics issues attributable to the pronounced hydrophobicity of Cer. Missense mutations of the protein p53, which have been detected in approximately 42% of cancer cases, not only lose the tumor suppression activity of wild-type p53, but also gain oncogenic functions promoting tumor progression and drug resistance. Our previous works showed that cellular Cer can eradicate cancer cells that carry a p53 deletion-mutation by modulating alternative pre-mRNA splicing, restoring wild-type p53 protein expression. Here, we report that new ceramide-rubusoside (Cer-RUB) nanomicelles considerably enhance Cer in vivo bioavailability and restore p53-dependent tumor suppression in cancer cells carrying a p53 missense mutation. Natural RUB encapsulated short-chain C6-Cer so as to form Cer-RUB nanomicelles (∼32 nm in diameter) that substantially enhanced Cer solubility and its levels in tissues and tumors of mice dosed intraperitoneally. Intriguingly, Cer-RUB nanomicelle treatments restored p53-dependent tumor suppression and sensitivity to cisplatin in OVCAR-3 ovarian cancer cells and xenograft tumors carrying p53 R248Q mutation. Moreover, Cer-RUB nanomicelles showed no signs of significant nonspecific toxicity to noncancerous cells or normal tissues, including bone marrow. Furthermore, Cer-RUB nanomicelles restored p53 phosphorylated protein and downstream function to wild-type levels in p53 R172H/+ transgenic mice. Altogether, this study, for the first time, indicates that natural Cer-RUB nanomicelles offer a feasible approach for efficaciously and safely targeting cancers carrying p53 missense mutations.
Collapse
Affiliation(s)
- Sachin K Khiste
- School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana
| | - Zhijun Liu
- School of Renewable Natural Resources, Louisiana State University Agricultural Center, Baton Rouge, Louisiana
| | - Kartik R Roy
- School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana
| | - Mohammad B Uddin
- School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana
| | - Salman B Hosain
- School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana
| | - Xin Gu
- Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, Louisiana
| | - Sami Nazzal
- Department of Pharmaceutical Sciences, Texas Tech University Health Science Center, Dallas, Texas
| | - Ronald A Hill
- School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana
| | - Yong-Yu Liu
- School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana.
| |
Collapse
|
11
|
Suhrland C, Truman J, Obeid LM, Sitharaman B. Delivery of long chain C16and C24ceramide in HeLa cells using oxidized graphene nanoribbons. J Biomed Mater Res B Appl Biomater 2019; 108:1141-1156. [DOI: 10.1002/jbm.b.34465] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Revised: 06/24/2019] [Accepted: 07/13/2019] [Indexed: 01/15/2023]
Affiliation(s)
- Cassandra Suhrland
- Department of Biomedical EngineeringStony Brook University Stony Brook New York
| | - Jean‐Philip Truman
- Department of Medicine and the Stony Brook Cancer Center, Health Science CenterStony Brook University Stony Brook New York
| | - Lina M. Obeid
- Department of Medicine and the Stony Brook Cancer Center, Health Science CenterStony Brook University Stony Brook New York
| | - Balaji Sitharaman
- Department of Biomedical EngineeringStony Brook University Stony Brook New York
| |
Collapse
|
12
|
Swider E, Maharjan S, Houkes K, van Riessen NK, Figdor C, Srinivas M, Tagit O. Förster Resonance Energy Transfer-Based Stability Assessment of PLGA Nanoparticles in Vitro and in Vivo. ACS APPLIED BIO MATERIALS 2019; 2:1131-1140. [PMID: 30906926 PMCID: PMC6428147 DOI: 10.1021/acsabm.8b00754] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2018] [Accepted: 02/05/2019] [Indexed: 02/06/2023]
Abstract
The knowledge of in vitro and in vivo stability of polymeric nanoparticles is vital for the development of clinical formulations for drug delivery and cell labeling applications. Förster resonance energy transfer (FRET)-based fluorescence labeling approaches are promising tools to study nanoparticle stability under different physiological conditions. Here, we present the FRET-based stability assessment of poly(lactic-co-glycolic acid) (PLGA) nanoparticles encapsulating BODIPY-FL12 and Nile Red as the donor and acceptor, respectively. The stability of PLGA nanoparticles is studied via monitoring the variations of fluorescence emission characteristics along with colloidal characterization. Accordingly, PLGA nanoparticles are colloidally stable for more than 2 weeks when incubated in aqueous buffers in situ, whereas in vitro particle degradation starts in between 24 and 48 h, reaching a complete loss of FRET at 72 h as shown with fluorescence microscopy imaging and flow cytometry analysis. PLGA nanoparticles systemically administered to mice predominantly accumulate in the liver, in which FRET no longer takes place at time points as early as 24 h postadministration as determined by ex vivo organ imaging and flow cytometry analysis. The results of this study expand our knowledge on drug release and degradation behavior of PLGA nanoparticles under different physiological conditions, which will prove useful for the rational design of PLGA-based formulations for various applications that can be translated into clinical practice.
Collapse
Affiliation(s)
- Edyta Swider
- Department
of Tumor Immunology, Radboud Institute for
Molecular Life Sciences, Nijmegen, HB 6500, The Netherlands
| | - Sanish Maharjan
- Department
of Tumor Immunology, Radboud Institute for
Molecular Life Sciences, Nijmegen, HB 6500, The Netherlands
| | - Karlijne Houkes
- Department
of Tumor Immunology, Radboud Institute for
Molecular Life Sciences, Nijmegen, HB 6500, The Netherlands
| | - Nicolaas Koen van Riessen
- Department
of Tumor Immunology, Radboud Institute for
Molecular Life Sciences, Nijmegen, HB 6500, The Netherlands
| | - Carl Figdor
- Department
of Tumor Immunology, Radboud Institute for
Molecular Life Sciences, Nijmegen, HB 6500, The Netherlands
- Oncode
Institute, Utrecht, AL 3521, The Netherlands
| | - Mangala Srinivas
- Department
of Tumor Immunology, Radboud Institute for
Molecular Life Sciences, Nijmegen, HB 6500, The Netherlands
| | - Oya Tagit
- Department
of Tumor Immunology, Radboud Institute for
Molecular Life Sciences, Nijmegen, HB 6500, The Netherlands
- Oncode
Institute, Utrecht, AL 3521, The Netherlands
| |
Collapse
|
13
|
Chen T, He B, Tao J, He Y, Deng H, Wang X, Zheng Y. Application of Förster Resonance Energy Transfer (FRET) technique to elucidate intracellular and In Vivo biofate of nanomedicines. Adv Drug Deliv Rev 2019; 143:177-205. [PMID: 31201837 DOI: 10.1016/j.addr.2019.04.009] [Citation(s) in RCA: 94] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2018] [Revised: 02/25/2019] [Accepted: 04/08/2019] [Indexed: 12/24/2022]
Abstract
Extensive studies on nanomedicines have been conducted for drug delivery and disease diagnosis (especially for cancer therapy). However, the intracellular and in vivo biofate of nanomedicines, which is significantly associated with their clinical therapeutic effect, is poorly understood at present. This is because of the technical challenges to quantify the disassembly and behaviour of nanomedicines. As a fluorescence- and distance-based approach, the Förster Resonance Energy Transfer (FRET) technique is very successful to study the interaction of nanomedicines with biological systems. In this review, principles on how to select a FRET pair and construct FRET-based nanomedicines have been described first, followed by their application to study structural integrity, biodistribution, disassembly kinetics, and elimination of nanomedicines at intracellular and in vivo levels, especially with drug nanocarriers including polymeric micelles, polymeric nanoparticles, and lipid-based nanoparticles. FRET is a powerful tool to reveal changes and interaction of nanoparticles after delivery, which will be very useful to guide future developments of nanomedicine.
Collapse
Affiliation(s)
- Tongkai Chen
- Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
| | - Bing He
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China
| | - Jingsong Tao
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China
| | - Yuan He
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China
| | - Hailiang Deng
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Xueqing Wang
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
| | - Ying Zheng
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.
| |
Collapse
|
14
|
Ghosh S, Lalani R, Patel V, Bardoliwala D, Maiti K, Banerjee S, Bhowmick S, Misra A. Combinatorial nanocarriers against drug resistance in hematological cancers: Opportunities and emerging strategies. J Control Release 2019; 296:114-139. [DOI: 10.1016/j.jconrel.2019.01.011] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2018] [Revised: 01/10/2019] [Accepted: 01/11/2019] [Indexed: 12/16/2022]
|
15
|
Zhang R, Billingsley MM, Mitchell MJ. Biomaterials for vaccine-based cancer immunotherapy. J Control Release 2018; 292:256-276. [PMID: 30312721 PMCID: PMC6355332 DOI: 10.1016/j.jconrel.2018.10.008] [Citation(s) in RCA: 106] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Revised: 10/06/2018] [Accepted: 10/08/2018] [Indexed: 12/28/2022]
Abstract
The development of therapeutic cancer vaccines as a means to generate immune reactivity against tumors has been explored since the early discovery of tumor-specific antigens by Georg Klein in the 1960s. However, challenges including weak immunogenicity, systemic toxicity, and off-target effects of cancer vaccines remain as barriers to their broad clinical translation. Advances in the design and implementation of biomaterials are now enabling enhanced efficacy and reduced toxicity of cancer vaccines by controlling the presentation and release of vaccine components to immune cells and their microenvironment. Here, we discuss the rational design and clinical status of several classes of cancer vaccines (including DNA, mRNA, peptide/protein, and cell-based vaccines) along with novel biomaterial-based delivery technologies that improve their safety and efficacy. Further, strategies for designing new platforms for personalized cancer vaccines are also considered.
Collapse
Affiliation(s)
- Rui Zhang
- Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, United States
| | - Margaret M Billingsley
- Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, United States
| | - Michael J Mitchell
- Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, United States; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.
| |
Collapse
|
16
|
Li W, Yi X, Liu X, Zhang Z, Fu Y, Gong T. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy. J Control Release 2016; 225:170-82. [DOI: 10.1016/j.jconrel.2016.01.049] [Citation(s) in RCA: 69] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2015] [Revised: 01/19/2016] [Accepted: 01/26/2016] [Indexed: 10/22/2022]
|
17
|
Rao S, Prestidge CA. Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery. Expert Opin Drug Deliv 2016; 13:691-707. [PMID: 26866382 DOI: 10.1517/17425247.2016.1151872] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION A number of biobarriers limit efficient oral drug absorption; both polymer-based and lipid-based nanocarriers have demonstrated properties and delivery mechanisms to overcome these biobarriers in preclinical settings. Moreover, in order to address the multifaceted oral drug delivery challenges, polymer-lipid hybrid systems are now being designed to merge the beneficial features of both polymeric and lipid-based nanocarriers. AREAS COVERED Recent advances in the development of polymer-lipid hybrids with a specific focus on their viability in oral delivery are reviewed. Three classes of polymer-lipid hybrids have been identified, i.e. lipid-core polymer-shell systems, polymer-core lipid-shell systems, and matrix-type polymer-lipid hybrids. We focus on their application to overcome the various biological barriers to oral drug absorption, as exemplified by selected preclinical studies. EXPERT OPINION Numerous studies have demonstrated the superiority of polymer-lipid hybrid systems to their non-hybrid counterparts in providing improved drug encapsulation, modulated drug release, and improved cellular uptake. These features have encouraged their applications in the delivery of chemotherapeutics, proteins, peptides, and vaccines. With further research expected to optimize the manufacturing and scaling up processes and in-depth pre-clinical pharmacological and toxicological assessments, these multifaceted drug delivery systems will have significant clinical impact on the oral delivery of pharmaceuticals and biopharmaceuticals.
Collapse
Affiliation(s)
- Shasha Rao
- a School of Pharmacy and Medical Sciences , University of South Australia , Adelaide , SA , Australia
| | - Clive A Prestidge
- a School of Pharmacy and Medical Sciences , University of South Australia , Adelaide , SA , Australia
| |
Collapse
|
18
|
Zhao S, Zhang S, Ma J, Fan L, Yin C, Lin G, Li Q. Double loaded self-decomposable SiO₂ nanoparticles for sustained drug release. NANOSCALE 2015; 7:16389-16398. [PMID: 26394069 DOI: 10.1039/c5nr03029c] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Sustained drug release for a long duration is a desired feature of modern drugs. Using double-loaded self-decomposable SiO2 nanoparticles, we demonstrated sustained drug release in a controllable manner. The double loading of the drugs was achieved using two different mechanisms-the first one via a co-growth mechanism, and the second one by absorption. A two-phase sustained drug release was firstly revealed in an in vitro system, and then further demonstrated in mice. After a single intravenous injection, the drug was controllably released from the nanoparticles into blood circulation with a Tmax of about 8 h, afterwards a long lasting release pattern was achieved to maintain drug systemic exposure with a plasma elimination half-life of approximately 28 h. We disclosed that the absorbed drug molecules contributed to the initial fast release for quickly reaching the therapeutic level with relatively higher plasma concentrations, while the "grown-in" drugs were responsible for maintaining the therapeutic level via the later controlled slow and sustained release. The present nanoparticle carrier drug configuration and the loading/maintenance release mechanisms provide a promising platform that ensures a prolonged therapeutic effect by controlling drug concentrations within the therapeutic window-a sustained drug delivery system with a great impact on improving the management of chronic diseases.
Collapse
Affiliation(s)
- Saisai Zhao
- Department of Physics, The Chinese University of Hong Kong, Shatin, New Territory, Hong Kong, China.
| | | | | | | | | | | | | |
Collapse
|
19
|
Stolzoff M, Ekladious I, Colby AH, Colson YL, Porter TM, Grinstaff MW. Synthesis and Characterization of Hybrid Polymer/Lipid Expansile Nanoparticles: Imparting Surface Functionality for Targeting and Stability. Biomacromolecules 2015; 16:1958-66. [PMID: 26053219 DOI: 10.1021/acs.biomac.5b00336] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The size, drug loading, drug release kinetics, localization, biodistribution, and stability of a given polymeric nanoparticle (NP) system depend on the composition of the NP core as well as its surface properties. In this study, novel, pH-responsive, and lipid-coated NPs, which expand in size from a diameter of approximately 100 to 1000 nm in the presence of a mildly acidic pH environment, are synthesized and characterized. Specifically, a combined miniemulsion and free-radical polymerization method is used to prepare the NPs in the presence of PEGylated lipids. These PEGylated-lipid expansile NPs (PEG-L-eNPs) combine the swelling behavior of the polymeric core of expansile NPs with the improved colloidal stability and surface functionality of PEGylated liposomes. The surface functionality of PEG-L-eNPs allows for the incorporation of folic acid (FA) and folate receptor-targeting. The resulting hybrid polymer/lipid nanocarriers, FA-PEG-L-eNPs, exhibit greater in vitro uptake and potency when loaded with paclitaxel compared to nontargeted PEG-L-eNPs.
Collapse
Affiliation(s)
| | | | | | - Yolonda L Colson
- §Division of Thoracic Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts 02115, United States
| | | | | |
Collapse
|
20
|
Liu Z, Zhao H, He L, Yao Y, Zhou Y, Wu J, Liu J, Ding J. Aptamer density dependent cellular uptake of lipid-capped polymer nanoparticles for polyvalent targeted delivery of vinorelbine to cancer cells. RSC Adv 2015. [DOI: 10.1039/c4ra16371k] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
In this work, MUC1 aptamer (designated S2.2) modified and vinorelbine (VRL) loaded lipid-polymer hybrid nanoparticles (Apt-VRL-NPs) were prepared.
Collapse
Affiliation(s)
- Zhenbao Liu
- School of Pharmaceutical Sciences
- Central South University
- Changsha 410013
- People's Republic of China
| | - Huanzhe Zhao
- School of Pharmaceutical Sciences
- Central South University
- Changsha 410013
- People's Republic of China
| | - Lingyun He
- School of Pharmaceutical Sciences
- Central South University
- Changsha 410013
- People's Republic of China
| | - Yao Yao
- School of Pharmaceutical Sciences
- Central South University
- Changsha 410013
- People's Republic of China
| | - Yanbin Zhou
- School of Pharmaceutical Sciences
- Central South University
- Changsha 410013
- People's Republic of China
| | - Jianping Wu
- School of Pharmaceutical Sciences
- Central South University
- Changsha 410013
- People's Republic of China
| | - Juewen Liu
- School of Pharmaceutical Sciences
- Central South University
- Changsha 410013
- People's Republic of China
- Department of Chemistry
| | - Jinsong Ding
- School of Pharmaceutical Sciences
- Central South University
- Changsha 410013
- People's Republic of China
| |
Collapse
|
21
|
Hybrid poly(lactic-co-glycolic acid) nanoparticles: design and delivery prospectives. Drug Discov Today 2014; 20:95-104. [PMID: 25277320 DOI: 10.1016/j.drudis.2014.09.018] [Citation(s) in RCA: 84] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2014] [Revised: 08/02/2014] [Accepted: 09/24/2014] [Indexed: 11/20/2022]
Abstract
Poly(lactic-co-glycolic acid) (PLGA), a US Food and Drug Administration (FDA)-approved copolymer, has been exploited widely in the design of nanoparticles because it is biodegradable, biocompatible, protects the drug molecules from degradation, and aids in producing sustained and targeted delivery. However, certain constraints associated with PLGA nanoparticles, such as poor drug encapsulation, polymer degradation, and scale-up issues, have led to the development of emerging hybrid PLGA delivery systems. These hybrid nanoparticles are core-shell nanostructures comprising either a PLGA core or a PLGA shell combining multiple functionalities within one system and, thus, exhibiting the complementary characteristics of two different platforms used for the delivery of a wide range of therapeutics and imaging.
Collapse
|